TARRYTOWN, N.Y., Nov. 02, 2026 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:
2026 Jefferies Global Healthcare Conference in London at 2:00 p.m. GMT (9:00 a.m. ET) on Tuesday, November 17, 2026
9th Annual Evercore Healthcare Conference at 1:45 p.m. ET on Tuesday, December 1, 2026
Citi’s 2026 Global Healthcare Conference at 9:40 a.m. ET on Wednesday, December 2, 2026
The sessions may be accessed from the “Investors & Media” page of Regeneron’s website at https://investor.regeneron.com/events-and-presentations. Replays and transcripts of the webcasts will be archived on the Company’s website for at least 30 days.
About Regeneron Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.
Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.
Exploration drill program in Q4 2026 is focused on Tibooburra Gold Project, New South Wales.
Novo will commence a ~2,700 m RC program at Tibooburra, NSW, with drilling at the Clone prospect anticipated to commence in early-November 2026.
Surface geochemical sampling including regional streams, targeted soils and rock chips; along with geological mapping was completed in Q3 2026. Assays are pending for the collected samples.
Egina and Farno Projects
Novo is undertaking a comprehensive review of all geological data relating to the Egina Gold Project, with the review aiming to identify targets for drilling programs at Egina in H1 2027, subject to all approvals being obtained.
Under the Farno JV with Northern Star Resources (NST), NST has been completing mapping, rock chip sampling, interpretation and soils resampling of historic AC holes. This is to develop a more holistic interpretation over the JV tenement.
Drill planning is now underway for a maiden RC drilling program at the Teichman Gold Project in Q1 2027. This program has been delayed due to on-going work to secure all regulatory and heritage access approvals.
Further soil sampling has been completed at the Teichman and follow up programs ongoing at the Egina project with results pending.
Onslow District, Western Australia
Novo are awaiting grant of tenement applications with planning underway for on-ground mapping and sampling reconnaissance programs as well as ground gravity and passive seismic geophysical surveys over the identified targets.
Wyloo Project, Western Australia
Follow up reconnaissance mapping and infill soil sampling occurred at the Vera and Kavira prospects in Q3 2026 with samples being analysed using the Ultrafine+™ analytical method. Follow up drilling is planned for 2027, subject to heritage approvals being obtained.
Belltopper Gold Project (Victoria) being advanced
Novo is considering all strategic options including securing a project partners for the potential advancement of the Belltopper Gold Project in Victoria.
Corporate
Increase in the value of Novo’s investment in San Cristobal MiningInc takes the value of the investment to A$36.2 million (C$35.9 million)
In line with the Joint Venture and Option agreement between Novo, Manhattan Gold Corporation Ltd and Awati Resources Pty Ltd (Awati) – a fully owned subsidiary of Manhattan Gold, Novo issued 1,500,000 common shares at the value of A$100k (C$99k) to Awati on 31 July 2026.
Cash balance of A$8.5 million (C$8.3 million) and investments of approximately A$38.1 million (C$37.7 million) as at 30 September 2026.
Novo Field Assistant conducting reconnaissance rock chip sampling at the Vera prospect at the Wyloo Polymetallic Project, Pilbara Region Western Australia.
PERTH, Australia, Nov. 02, 2026 (GLOBE NEWSWIRE) — Novo Resources Corp. (Novo or the Company) (ASX: NVO) (TSX: NVO) (OTCQB: NSRPF) is pleased to report on the recent and planned key activities of the Company.
PORTFOLIO
Novo continues to assemble a diversified gold exploration and development portfolio located across leading mining provinces in Australia, comprising a mix of greenfields, advanced greenfields, and advanced exploration projects.
A dedicated project generation program continues to focus on identifying advanced gold and copper assets to further enhance Novo’s portfolio.
WESTERN AUSTRALIAN PORTFOLIO
Exploration programs completed across the Company’s Pilbara project portfolio (Figure 1) have provided several high-priority drill targets where RC drilling is planned for 2027, subject to grant of tenements and land access approvals.
Figure 1: Novo Pilbara and Onslow tenure showing main projects and significant prospects.
Wyloo Polymetallic Project
In Q2 2026, soil sampling and rock chip samples were collected to the southeast of the Wyloo SE prospect. A total of 142 minus 80 mesh soil samples were collected at a 80 m x 20 m spacing highlighting the 600 m long, 270 m wide Vera antimony – arsenic soil anomaly which is open to the north and east (Figure 2).
Figure 2. Stream sediment and rock Sb assay results over geology, showing the Kavira and Vera prospects to the west and east of Wyloo SE
The field team has recently completed follow up on-ground soil sampling at the Vera and Kavira prospects, located to the east and west (respectively) of Wyloo SE (Figure 2). This fieldwork has been focussed on defining the extent of the mineralised system across the southern portion of the Wyloo E47/4213 tenement. Ongoing work over the Kavira stream sediment anomaly was completed in Q3 2026. This infill soil sampling is being analysed using the Ultrafine+™, an analytical technique designed to detect anomalism beneath Tertiary transported cover, with results still pending.
Fieldwork at the Vera and Kavira prospects is progressing in preparation for an AC drilling program planned for 2027, designed to drill under the Tertiary transported cover, subject to the receipt of land access approvals including heritage surveys.
Egina Gold Camp
As previously advised by Novo on 27 May 2026 (refer to Novo’s ASX announcement entitled “Egina Gold Project Update”), Northern Star Resources Ltd (ASX:NST) (NST) informed Novo that they are withdrawing from the earn-in under the Egina Earn In and Joint Venture Agreement.
The data from Northern Star’s recent exploration activities is being reviewed and soil sampling within the Egina Gold Project tenements is ongoing in November 2026. Novo has engaged Consultant Geologist Allan Kneeshaw, who was involved with the discovery of the Hemi Gold Project, to review the litho-geochemistry of the Egina Gold Project and assist Novo’s geological team in identifying gold mineralisation targets adjacent to the Millindinna Intrusive Suite in preparation for drilling programs in 2027. An update on the results of this review is planned for release in December 2026.
The Millindinna Intrusive Suite is an Archean layered mafic – ultramafic intrusive suite which has intruded older sedimentary sequences in the Mallina Basin. The Suite is closely associated with regional exploration targets, including intrusive gold systems (such as Hemi-style targets).
Figure 3 – Egina Gold Project and Egina Gold Camp Tenements.
Target areas along structural corridors related to the suite are considered highly prospective for Hemi style gold mineralisation and will be the focus of the Novo geological team’s exploration field work in the Pilbara Craton’s Central Pilbara Tectonic Zone.
Farno Joint Venture
Under the Farno JV with Northern Star Resources (NST), NST has been completing mapping, rock chip sampling, interpretation and spoils resampling of historic AC holes. This is to develop a more holistic interpretation over the JV tenement.
NST proposes on-ground gravity and Induced Polarisation (IP) geophysical surveys of the Farno JV tenement, E47/2502, subject to land access approvals. The geophysical surveys are designed to develop targets for potential drill testing.
However, due to heritage constraints exploration has been limited to low impact activities in areas which can be accessed.
Teichman Gold Project
Novo is also advancing gold exploration at the Teichman Gold Project, which is part of the Croydon JV (70% Novo and 30% Runnel Holdings Pty Ltd, an entity of Mark Gareth Creasy (Creasy Group)).
The project area includes multiple historic workings centred on two main mineralised shear zones, over an area of approximately 2.5 km by 1.3 km. Previous exploration at Teichman included mapping and surface sampling and has defined multiple shear-hosted gold targets along the Pride and Teichman trends (Figure 4).
On ground fieldwork undertaken this month consisted of gridded soil sampling designed to further define targets for a maiden RC drilling program. Results from this sampling are still pending. This program followed discussions with the Mugarinya Community, which facilitated Novo’s access to the Yandeyarra Reserve to undertake low-impact exploration.
Heritage surveys are planned to clear a program of RC drilling for H1 2027 following delays in heritage access agreements being finalised.
Figure 4 –Teichman prospects highlighting Novo rock chip results > 5 g/t Au and geological interpretation with regolith cover.1
BELLTOPPER GOLD PROJECT – VICTORIA
Internal mining studies completed based on the updated Exploration Target announced in February 2026, that assumed underground mining and toll treatment, support the current evaluation of development options for the Belltopper Gold Project in Victoria.
Novo is considering all strategic options including securing a project partner for the potential development of the project. Recent mining approvals within Victoria, including the exploration tunnel at Southern Cross Gold’s Sunday Creek Project, provides confidence that the regulatory environment within Victoria can support further consideration of an appropriately assessed and studied underground gold project at Belltopper.
Work continues to define the potential of Belltopper. The selection of preliminary drill site location selection has commenced for potential drilling in H1 2027, aiming to provide further confidence in the updated 2026 Exploration Target (Figure 5) and the definition of further potential reefs.
A program of 2,500 m of diamond drilling will target a number of known and expected reefs in the core central portion of the Exploration Target, focussed at the Belltopper anticline and converging reefs in the nose of the structure.
Figure 5 – Overview Map of the Belltopper Gold Project showing location of the eight reefs included in the 2026 Exploration Target, downhole gold tenor, historical workings, and important geological elements of the field.
A ~2,700 m Reverse Circulation (RC) drilling program is scheduled to commence at the Tibooburra Gold Project (Tibooburra) (Figure 6) in Q4 2026, as Novo has now obtained all required regulatory and land holder approvals. RC drilling is planned to test the Clone prospect (~2,700 m) and follow up the results of the 2025 drilling program that identified plunging high-grade shoots that are open in multiple directions.
Figure 7 – Location, tenure and key prospects at Tibooburra, NSW. Tenements EL9867 and EL9900 are newly granted (and 100% owned by Novo). All other tenements belong to the Tibooburra Gold Project Farm-In JV with Awati Resources Pty Ltd (wholly owned subsidiary of Manhattan Gold Corporation Ltd).
Regional stream sediment sampling, coupled with targeted mapping and gridded surface soil sampling, commenced in September and a follow up sampling program is underway. This fieldwork aims to generate new gold-anomalous zones in potentially recessive areas on the 30 km long Albert Goldfield, grow the target pipeline, and help prioritise those targets for potential future exploration drilling in H1 2027.
SUSTAINABILITY
There were no safety, environmental or heritage incidents reported during Q3.
Discussions with representatives of various Traditional Owners are ongoing as Novo reviews and updates the relevant access agreements. Novo continues to work closely with the Mugarinya Community Board, whose approval is required to allow exploration drilling to take place within the Yandeyarra Reserve once Western Australian Government approval has also been received. Novo remains in close contact with Traditional Owners to ensure appropriate heritage protection for planned exploration activities across all of its projects.
CORPORATE
Project Generation
Novo continues to focus its efforts on a dedicated and disciplined project generation program to identify value accretive opportunities across targeted gold and copper assets that complement the Company’s current portfolio. The Company is currently working on potential opportunities with third parties, none of which are sufficiently advanced to warrant disclosure, and the Company will make an announcement if and when any of these opportunities become formal and binding.
Comet Well and Purdy’s North
As announced in February 2025, Novo’s board of directors resolved to seek interest from parties to acquire or be part of a joint venture in relation to the Comet Well and Purdy’s North project. This process remains on-going. As part of this decision, a sale process for the Mechanical Ore Sorter is underway.
Relinquishment of Tenure
The Company’s exploration programs across key Pilbara areas continue to successfully identify priority targets for follow-up drilling, while also identifying tenure that provides little further exploration value.
As a result, tenure which does not complement Novo’s exploration strategy continues to be relinquished to reduce land tenure holding costs.
The Company currently manages an estimated ~5,620 sq km of 100% owned tenure, of which ~626 sq km of tenure forms the Harding Dam Battery Metal Joint Venture (SQM Priority tenements), both managed by our JV partners. Novo has reduced annual holding costs by entering into joint ventures, or by relinquishing or divesting tenure of limited prospectivity.
Financial Update
As of 30 September 2026, Novo had a cash balance of A$8.5 million (C$8.3 million).
In addition, Novo has an investment portfolio of shares held in ASX-listed and unlisted companies that is valued at approximately A$38.1 million (C$37.7 million), consisting of:
(1) ASX-listed companies, valued at approximately A$1.5 million (C$1.5 million) based on the closing price of those shares on 30 September 2026; and
(2) Unlisted companies, valued at approximately A$36.6 million (C$36.3 million) as of 30 September 2026.
Ticker
Number of shares held
Novo’s interest
Value A$’000
Value C$’000
(1) ASX-listed shares
Kalamazoo Resources Limited
ASX: KZR
10,000,000
2.63%
$1,450
$1,437
Kali Metals Limited (commenced trading 8 January 2024)
ASX: KM1
566,947
0.28%
$52
$52
(2) Unlisted shares*
Elementum 3D Inc. (E3D)
N/A
2,076,560
8.63%
$416
$412
San Cristobal Mining Inc. (SCM)
N/A
1,242,500
2.39%
$36,193
$35,860
* The investment portfolio values shown are in line with management’s valuation as at 30 September 2026.
Share Registry
A snapshot of Novo’s top 10 shareholders as at 30 September 2026 is set out below for reference*.
*Please note that the above list of shareholders excludes the objecting beneficial owners and non-objecting beneficial owners as defined in National Instrument 54-101 Communication with Beneficial Owners of Securities of a Reporting Issuer published by the Canadian Securities Administrators, and these shareholders with holdings above 1% hold approximately 8% of the register.
Authorised for release by Board of Directors.
CONTACT
Investors:
Mike Spreadborough +61 8 6400 6100 info@novoresources.com
North American Queries:
Leo Karabelas. +1 416 543 3120 leo@novoresources.com
Media:
Peter Tayler. +61 412 036 231 peter@nwrcommunication.com.au
QP STATEMENT
Mr Rohan Williams (MAusIMM), is the qualified person, as defined under National Instrument 43-101 Standards of Disclosure for Mineral Projects, responsible for, and having reviewed and approved, the technical information contained in this news release, as well as having verified the data disclosed, including sampling, analytical and test data underlying the information or opinions contained in the written disclosure. Mr Williams is the General Manager, Exploration at Novo.
Dr Christopher Doyle (MAIG) and Dr Simon Dominy (FAusIMM CPGeo; FAIG RPGeo), are the qualified persons, as defined under National Instrument 43-101 Standards of Disclosure for Mineral Projects, responsible for, and having reviewed and approved, the technical information contained in this news release that relates to the Belltopper Exploration Target. Dr Doyle is Novo’s Exploration Manager – Victoria and Dr Dominy is a Technical Advisor to Novo.
JORC COMPLIANCE STATEMENTS
Previous Exploration Results
The information in this news release that relates to Exploration Results from Novo’s Teichman Project is extracted from Novo’s ASX announcement entitled “Strong Gold Results from Teichman; High-Grade Antimony Results from Sherlock” dated 11 November 2025, and is available to view at www.asx.com.au. The Company confirms that it is not aware of any new information or data that materially affects the information included in the original market announcement and that all material assumptions and technical parameters underpinning the estimates in the market announcement continue to apply and have not materially changed. The Company confirms that the form and context in which the Competent Person’s findings are presented have not been materially modified from the original market announcement.
Belltopper Exploration Target
Novo initially announced its updated 2026 Exploration Target for Belltopper to ASX on 11 February 2026 in its announcement entitled “Novo Delivers Significant Increase to Belltopper Exploration Target” (which is available to view at www.asx.com.au) (Exploration Target Announcement).
The information in this announcement that relates to the Belltopper Exploration Target is based on information compiled by:
(a) Dr Christopher Doyle, a Competent Person who is a Member of the Australasian Institute of Geoscientists (MAIG). Dr Doyle is Exploration Manager – Victoria for Novo and is a full-time employee of Novo. Dr Doyle has sufficient experience that is relevant to the style of mineralisation and type of deposit under consideration and to the activity being undertaken to qualify as a Competent Person as defined in the 2012 Edition of the “Australasian Code for Reporting of Exploration Results, Mineral Resources and Ore Reserves”. Dr Doyle consents to the inclusion in this announcement of the matters based on his information in the form and context in which it appears; and
(b) Dr Simon Dominy, a Competent Person who is a Fellow of both the Australasian Institute of Geoscientists (FAIG RPGeo) and the Australasian Institute of Mining and Metallurgy (FAusIMM CPGeo). Dr Dominy is a Technical Advisor contracted to Novo. Dr Dominy has sufficient experience that is relevant to the style of mineralisation and type of deposit under consideration and to the activity being undertaken to qualify as a Competent Person as defined in the 2012 Edition of the “Australasian Code for Reporting of Exploration Results, Mineral Resources and Ore Reserves”. Dr Dominy consents to the inclusion in this announcement of the matters based on his information in the form and context in which it appears.
As a basis for the Belltopper Exploration Target, Novo applied its geological understanding of the reef network at Belltopper, drawing upon 3D reconstruction of historic mining and exploration data, drilling data, structural and geochemical data, field mapping (including high-resolution LiDAR™ interpretation), and surface rock chip sampling. Further information about Novo’s Exploration Target at Belltopper, along with a more detailed explanation of the basis for the Exploration Target (including a specific description of the level of exploration activity already completed at Belltopper), is contained in the Exploration Target Announcement.
DISCLAIMER
This Business Review constitutes a voluntary disclosure by the Company and is not a Quarterly Activities Report for the purposes of ASX Listing Rules 5.3 and 5.5 for which Novo has an exemption, as a foreign entity with its primary listing on an overseas exchange with a particular obligation imposed by the home exchange that is comparable to the ASX Listing Rule obligation.
FORWARD-LOOKING INFORMATION
Some statements in this news release may contain “forward-looking statements” within the meaning of Canadian and Australian securities law and regulations. In this news release, such statements include but are not limited to planned exploration activities and the timing of such. These statements address future events and conditions and, as such, involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the statements. Such factors include, without limitation, customary risks of the resource industry and the risk factors identified in Novo’s annual information form for the year ended December 31, 2025 (which is available under Novo’s profile on SEDAR+ at www.sedarplus.ca and at www.asx.com.au), and in the Company’s options prospectus dated 9 March 2026 and in the Company’s prospectus dated 2 August 2023, both of which are available at www.asx.com.au. Forward-looking statements speak only as of the date those statements are made. Except as required by applicable law, Novo assumes no obligation to update or to publicly announce the results of any change to any forward-looking statement contained or incorporated by reference herein to reflect actual results, future events or developments, changes in assumptions or changes in other factors affecting the forward-looking statements. If Novo updates any forward-looking statement(s), no inference should be drawn that the Company will make additional updates with respect to those or other forward-looking statements.
ABOUT NOVO
Novo is an Australian based gold explorer listed on the ASX and the TSX focussed on discovering standalone gold and copper projects with > 1 Moz Aueq development potential. Novo is an innovative gold explorer with a significant land package covering approximately 5,608 square kilometres in the Pilbara region of Western Australia, along with the 22 square kilometre Belltopper project in the Bendigo Tectonic Zone of Victoria, Australia. In addition to the above, Novo is part of a farm in agreement in New South Wales.
Novo has a significant investment portfolio and a disciplined program in place to identify value accretive opportunities that will build further value for shareholders.
Please refer to Novo’s website for further information including the latest corporate presentation.
#Refer to De Grey’s ASX Announcement, Hemi Gold Project mineral Resource Estimate (MRE) 2024, dated 14 November 2024. No assurance can be given that a similar (or any) commercially viable mineral deposit will be determined at Novo’s Becher Project.
_________________________________ 1 Refer to Novo’s ASX announcement dated 11 November 2025/news release disseminated in North America on November 11. 2025 – Strong Gold Results from Teichman; High-Grade Antimony Results from Sherlock
Photos accompanying this announcement are available at
Global fashion icon and A Thousand Wishes muse Valentina Ferrer connects the fragrance’s signature spirit with a wider international audience and a new generation of consumers.
The fragrance icon inspires two new scents, A Thousand Wishes Granted and A Thousand Crystal Wishes, a new solid perfume format and a holiday campaign featuring global fashion icon Valentina Ferrer
What you should know:
Bath & Body Works is celebrating A Thousand Wishes, one of its most-loved fragrance icons, with two new interpretations of the original scent: A Thousand Wishes Granted and A Thousand Crystal Wishes
The collection introduces a new solid perfume format for A Thousand Wishes and A Thousand Wishes Granted, offering consumers another way to wear and layer the fragrances.
A Thousand Crystal Wishes introduces a collectible new eau de parfum, embellished with crystals by Swarovski. Just 1,000 individually numbered bottles were created, a nod to the fragrance’s thousand wishes inspiration, and will be available through Bath & Body Works Drops on November 11 and at select stores while supplies last.
Global fashion icon and A Thousand Wishes muse Valentina Ferrer brings the fragrance’s signature spirit to a wider international audience and a new generation of consumers.
The launch brings Bath & Body Works’ Consumer First Formula to one of its biggest fragrance icons, pairing product upgrades and a holiday campaign with wider access through Ulta Beauty, Amazon and Drops.
COLUMBUS, Ohio, Nov. 02, 2026 (GLOBE NEWSWIRE) — This holiday, Bath & Body Works is celebrating the iconic fragrance A Thousand Wishes with the introduction of two new interpretations of the original: A Thousand Wishes Granted and A Thousand Crystal Wishes. New solid perfume formats offer another way to wear both A Thousand Wishes and A Thousand Wishes Granted, while A Thousand Crystal Wishes completes the collection with a collectible eau de parfum embellished with crystals by Swarovski. The launch comes to life through a holiday campaign featuring global fashion icon and A Thousand Wishes muse Valentina Ferrer.
The Original Favorite, A Thousand Wishes
Since its launch in 2014, A Thousand Wishes has become one of Bath & Body Works’ most enduring fragrance icons. Featuring notes of pink prosecco, sparkling quince, crystal peonies, gilded amber and amaretto crème, the fragrance is known for its sparkling character and association with celebration, making it a favorite for both gifting and everyday wear.
More than 10 years later, A Thousand Wishes continues to rank among Bath & Body Works’ most-loved fragrances. The fragrance has generated over $1 billion in total sales since launch and ranked among the brand’s top five fragrances by total shop sales in 2025.
The expansion reflects Bath & Body Works’ Consumer First Formula, including product innovation through new formats, enhanced fragrance quality through higher fragrance concentrations and expanded access through Bath & Body Works stores, Ulta Beauty and Amazon. Together, these enhancements give consumers more ways to discover, wear, and enjoy one of the brand’s most loved fragrance icons.
“A Thousand Wishes has become a Bath & Body Works icon because of its ability to evoke joy, celebration and emotional connection through fragrance,” said Mary Testa-Gough, assistant vice president of product & fragrance development at Bath & Body Works. “As we continue to invest in our most loved fragrances, we remain focused on elevating every touchpoint of the scent experience through enhanced fragrance quality, improved longevity, and innovative formats that enable consumers to build a fragrance wardrobe for every mood, moment, and ritual.”
Meet A Thousand Wishes Granted
The collection expands this season with the introduction of A Thousand Wishes Granted, a fragrance that builds on the spirit of the original while offering a new scent experience. The fragrance combines bright fruit notes of wild raspberry accord and fresh bergamot with warm, soft marshmallow musk and golden amber for a more intimate expression of the original.
Consumers will also find new ways to enjoy the collection with the introduction of solid perfume for both A Thousand Wishes and A Thousand Wishes Granted. The portable format offers a convenient way to refresh and layer the fragrances throughout the day, while the dermatologist-approved* formula glides onto skin with a lightweight feel.
The collection also features enhancements across select fragrance and body care products, including higher fragrance concentrations in fine fragrance mist and eau de parfum for longer-lasting wear, along with refreshed packaging.
Embellished with Swarovski® Crystals: A Thousand Crystal Wishes
A Thousand Crystal Wishes brings the most elevated expression to the collection, featuring notes of sparkling raspberry, sugared jasmine, crystal muguet, pink patchouli and sheer woods, the limited-edition eau de parfum was crafted with the highest fragrance load in the Bath & Body Works portfolio, creating a rich and long-lasting fragrance experience. Presented in an individually numbered bottle, the limited-edition eau de parfum is designed as both a fragrance and collectible keepsake, complete with a removeable bow charm, embellished with Swarovski Crystals, extending the experience beyond the fragrance itself.
In a nod to the fragrance’s a thousand wishes inspiration, only 1,000 individually numbered bottles were created. The limited-edition fragrance will launch on 11/11, a date chosen to reinforce the collection’s wish-inspired storytelling. A Thousand Crystal Wishes will be available through Bath & Body Works Drops and at select stores.
Celebrating the Magic of a Wish: Introducing A Thousand Wishes Muse Valentina Ferrer
Brought to life through a holiday campaign starring global fashion icon and A Thousand Wishes muse Valentina Ferrer, the collection celebrates the optimism, possibility and joy that have defined the fragrance since 2014, while introducing its signature spirit to a new generation around the world.
Inspired by the idea that every wish holds possibility, the campaign captures Ferrer through a world of light, reflection and celebration, showcasing the optimism and wonder that have long defined A Thousand Wishes. Through imagery of water and movement, the creative highlights the transformative power of making a wish and embracing what comes next.
“There’s something beautiful about making a wish. It’s a moment where you allow yourself to dream without limits and imagine everything that could be ahead of you,” said Ferrer. “A Thousand Wishes by Bath & Body Works captures a sense of optimism and celebration, which makes it feel especially fitting during the holidays when you’re reflecting on wishes, dreams and the moments that matter most.”
The campaign will debut during the Latin GRAMMY Awards, including a Spanish-language adaptation of the creative, and will appear across social media, YouTube and digital platforms throughout the holiday season.
Availability
A Thousand Wishes
Available now at Bath & Body Works stores nationwide and online at bathandbodyworks.com.
Available now at Ulta Beauty stores nationwide and online at Ulta.com.
Available throughout the United States and Canada.
Products range from approximately $13 to $70.
A Thousand Wishes Granted
Available on Amazon beginning November 16.
Available throughout the United States and Canada.
Products range from approximately $13 to $70.
A Thousand Crystal Wishes
Available exclusively through Bath & Body Works Drops and in select Bath & Body Works stores.
Available in the United States.
Looking Ahead
The A Thousand Wishes franchise is expected to expand internationally beginning in spring 2027.
ABOUT BATH & BODY WORKS
Bath & Body Works is a global leader in personal care and home fragrance, driven by the belief that everybody deserves to feel good.
The brand’s beloved scents are expertly crafted for performance and a luxury fragrance experience. Formulated with thoughtfully chosen ingredients, Bath & Body Works body care products are available in multiple forms, including fine fragrance mist, body cream, lotion, eau de parfum, body wash, hand soap, sanitizer and more. The brand’s 3-wick candles are made with high-quality fragrance oils layered throughout a premium soy wax base for up to 45 hours of room-filling fragrance.
Consumers can shop Bath & Body Works in more than 1,900 stores in the U.S. and Canada, 550-plus international locations and select Ulta Beauty stores. Online, consumers can visit bathandbodyworks.com, Amazon and Ulta.com.
*Based on review of independent testing by board-certified dermatologist
NESS ZIONA, Israel, Nov. 02, 2026 (GLOBE NEWSWIRE) — Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX) (“Foresight” or the “Company”), an innovator in 3D perception systems, today issued a reminder, further to its announcement dated September 30, 2026, regarding the voluntary delisting of its ordinary shares, no par value per share (the “Ordinary Shares”), from trading on the Tel Aviv Stock Exchange Ltd. (“TASE”). The Company encourages holders of Ordinary Shares traded on the TASE to contact their banks or brokers to arrange for the conversion of their Ordinary Shares into American Depositary Shares (“ADSs”).
As previously announced, the last day of trading of the Ordinary Shares on the TASE will be January 1, 2027, and the Ordinary Shares will be delisted from the TASE on January 4, 2027.
The Company’s ADSs, each currently representing ninety (90) Ordinary Shares, will continue to be listed and trade on the Nasdaq Capital Market (“Nasdaq”), under the symbol “FRSX.” The voluntary delisting from the TASE will not affect the Company’s listing on Nasdaq or its reporting obligations under U.S. securities laws.
The Bank of New York Mellon (“BNY”), the depositary for the Company’s ADS program, will waive its issuance fees for the conversion of Ordinary Shares into ADSs through January 7, 2027. Beginning January 8, 2027, BNY will charge issuance fees of $5.00 per 100 ADSs delivered or a fraction thereof. The waiver applies only to BNY’s issuance fees; shareholders should consult their banks or brokers regarding any other applicable fees or charges.
Shareholders are encouraged to review the guide and contact their banks or brokers promptly to allow sufficient time to complete the conversion and benefit from BNY’s fee waiver.
To convert Ordinary Shares into ADSs, shareholders should instruct their banks or brokers to deposit the Ordinary Shares with one of BNY’s Israeli custodians identified in the conversion guide and provide complete delivery instructions. Deposits must result in the issuance of whole ADSs; deposits resulting in fractional ADSs will be rejected by the custodians.
Shareholders should confirm in advance that their receiving broker is able to accept delivery of the ADSs through The Depository Trust Company (“DTC”). Unless the Company makes special arrangements with BNY, deliveries after January 7, 2027, will be made on a delivery-versus-payment basis for the applicable issuance fees. The receiving DTC broker must accept delivery and payment of those fees for settlement to be completed.
About Foresight
Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX) is a technology company developing advanced three-dimensional (3D) perception systems and cellular-based applications. Through its wholly owned subsidiaries, Foresight Automotive Ltd., Foresight Changzhou Automotive Ltd., and Eye-Net Mobile Ltd., Foresight develops both “in-line-of-sight” vision systems and “beyond-line-of-sight” accident-prevention solutions.
Foresight’s 3D perception systems include modules of automatic calibration and dense 3D point cloud that can be applied to different markets such as automotive, defense, autonomous driving, agriculture, heavy industrial equipment, and UAVs.
Eye-Net Mobile develops next-generation vehicle-to-everything collision prevention solutions and smart automotive systems to enhance road safety and situational awareness for all road users in urban mobility environments. By leveraging cutting-edge artificial intelligence technology, advanced analytics, and existing cellular networks, Eye-Net’s innovative solution suite delivers real-time pre-collision alerts to all road users via smartphones and other smart devices within vehicles.
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “aims,” “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, Foresight is using forward-looking statements in this press release when it discusses the voluntary delisting from the TASE, the last trading day and delisting date of the Ordinary Shares on the TASE, the continued listing and trading of the ADSs on Nasdaq, and the anticipated arrangements for conversion of Ordinary Shares into ADSs, including BNY’s issuance fee waiver and subsequent issuance fees and settlement procedures. Because such statements deal with future events and are based on Foresight’s current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements of Foresight could differ materially from those described in or implied by the statements in this press release.
The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in Foresight’s annual report on Form 20-F for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on March 25, 2026, and in any subsequent filings with the SEC. Except as otherwise required by law, Foresight undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Foresight is not responsible for the content of third party websites.
Investor Relations Contact: Miri Segal-Scharia CEO MS-IR LLC msegal@ms-ir.com
All financial figures are in Canadian dollars unless otherwise noted
CALGARY, Alberta, Nov. 02, 2026 (GLOBE NEWSWIRE) — Gibson Energy Inc. (TSX:GEI) (“Gibson”, or the “Company”) announced today that its Board of Directors has approved a quarterly dividend of $0.45 per common share, payable on January 15, 2027, to shareholders of record at the close of business on December 30, 2026. This dividend is designated as an eligible dividend for Canadian income tax purposes. For non-resident shareholders, Gibson’s dividends are subject to Canadian withholding tax.
About Gibson Gibson is a leading liquids infrastructure company providing storage, optimization, processing, gathering, and waterborne vessel loading services for liquids and refined products. Headquartered in Calgary, Alberta, the Company’s operations are located across North America, with core terminal assets in Hardisty and Edmonton, Alberta, Ingleside and Wink, Texas, and a facility in Moose Jaw, Saskatchewan.
Gibson shares trade under the symbol GEI and are listed on the Toronto Stock Exchange. For more information, visit www.gibsonenergy.com.
Dr. Shahidi brings extensive drug development experience, regulatory success, and transformative operational expertise to the Board
Mechelen, Belgium; November 2, 2026, 22.01 CET; Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced the appointment by way of co-optation of Dr. Mehdi Shahidi as Non-Executive Independent Director to its Board of Directors, effective November 2, 2026. He replaces Dr. Paulo Fontoura, who resigned from the Board in July 2026 following his appointment as the Global Head of R&D at Sanofi SA.
“We are thrilled to welcome Mehdi to the Board. I’m confident his extensive experience in drug development, history of regulatory success, and track record of building organizations will strengthen the Board’s ability to provide strategic guidance to Lakefront as it continues to advance gamgertamig and its preclinical assets, while maintaining a disciplined approach to deploying its strategic capital,” said Gino Santini, Chair of the Board of Directors.
Biography Dr. Mehdi Shahidi is a physician-scientist and an accomplished drug development and R&D leader with over 20 years of biopharma experience spanning translational research, clinical development, regulatory and successful introduction of innovative medicines to patients worldwide. His career combines senior leadership in global pharmaceutical R&D with entrepreneurial, venture capital, and board-level experience. He is currently Head of Development and Chief Medical Officer at Ottimo Pharma, Venture Partner at Medicxi, and a founder of Petalion Therapeutics. Previously, Dr. Shahidi served as SVP, Global Head of Medicine and CMO at Boehringer Ingelheim, where he led a large, global organization with a broad therapeutic mandate. During his tenure, he provided strategic and scientific oversight across a diverse portfolio of drug development programs, from early clinical development through multiple successful global regulatory approvals across various therapeutic areas. Dr. Shahidi previously served on the Supervisory Board of CureVac through its acquisition by BioNTech, as well as on the Innovation Committees of EFPIA and TransCelerate and the PhRMA R&D Leadership Forum. A clinical oncologist and GMC-registered specialist in pharmaceutical medicine, Dr. Shahidi completed his oncology training at the Royal Marsden Hospital and conducted clinical research at the Institute of Cancer Research, London.
About Lakefront Biotherapeutics Lakefront Biotherapeutics is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need. The Company has established a clinical-stage portfolio in immunology and inflammation, anchored by gamgertamig, a potential first-in-class and best-in-class BCMAxCD3 T-cell engager for autoimmune diseases. Backed by deep deal-making expertise, operational flexibility, and a strong capital position, Lakefront identifies, acquires, and advances high-quality assets with clear potential to deliver meaningful patient impact and long-term shareholder value. For more information, visit https://www.lakefrontbio.com or follow us on LinkedIn or X.
For further information, contact Lakefront Biotherapeutics: Investor Relations
Forward-looking statements This press release may include forward-looking statements, all of which involve certain risks and uncertainties. These statements are often, but not always, made through the use of words or phrases such as “will,” “long-term,” and “forward,” and any similar expressions. These statements include, but are not limited to, statements regarding the appointment of a new director, the expected benefits associated with the changes to Lakefront’s Board, and Lakefront’s ability to deliver meaningful impact for patients and sustainable value for shareholders. Any forward-looking statements in this press release are based on Lakefront’s management’s current expectations and beliefs and are not guarantees of future performance. Forward-looking statements may involve unknown and known risks, uncertainties and other factors which might cause Lakefront’s actual results, performance, or achievements to be materially different from any historic or future results, performance, or achievements expressed or implied by such statements. These risks, uncertainties and other factors include, without limitation, the risk that Lakefront may not be able to realize the expected benefits from the appointment of the new director. A further list and description of these risks, uncertainties and other factors can be found in Lakefront’s filings and reports with the Securities and Exchange Commission (SEC), including in Lakefront’s most recent annual report on Form 20-F filed with the SEC, as supplemented and/or modified by any other filings and reports that Lakefront has made or will make with the SEC in the future. Given these risks and uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. In addition, even if Lakefront’s results, performance, or achievements are consistent with such forward-looking statements, they may not be predictive of results, performance, or achievements in future periods. These forward-looking statements speak only as of the date of publication of this press release. Lakefront expressly disclaims any obligation to update any forward-looking statements in this press release, unless required by law or regulation.
– Keith A. Goldan to retire as CFO and remain with the Company through year-end to support the transition –
NEW YORK, Nov. 02, 2026 (GLOBE NEWSWIRE) — Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced the appointment of Aaron A. Ondrey as Chief Financial Officer, effective November 9, 2026. Mr. Ondrey brings to Syndax more than 25 years of financial and operational leadership experience across the biotechnology industry, with deep expertise in financial management, corporate strategy, commercialization, and mergers and acquisitions.
Current Chief Financial Officer Keith A. Goldan has decided to retire from the position and will remain with the Company through the end of 2026 to support the transition. Mr. Goldan led Syndax’s financial and capital strategy during an important period in the Company’s history. He played a key role in the successful launches of Revuforj and Niktimvo and in initiatives that strengthened the Company’s pipeline and innovative R&D platform.
“On behalf of the Board and our entire team, I thank Keith for his many valuable contributions and wish him all the best in his well-earned retirement,” said Michael A. Metzger, Chief Executive Officer of Syndax. “Keith was integral to Syndax’s transition into a commercial-stage company and the delivery of three FDA approvals, and he helped lay the foundation for our long-term success.”
Mr. Metzger continued, “We are delighted to welcome Aaron to Syndax. He brings decades of experience guiding biopharma companies through commercial expansion and major milestones. The Board and I are confident he will successfully lead our financial strategy and organization as we scale our commercial business, advance our deep pipeline and deliver long-term shareholder value.”
“I am thrilled to join Syndax at such a pivotal moment in the Company’s evolution,” said Aaron A. Ondrey. “Syndax has built an impressive commercial platform with two approved medicines and a compelling pipeline targeting significant market opportunities. I look forward to partnering with Michael and the broader Syndax team to build on the Company’s leadership position and its strong financial foundation.”
“It has been a privilege to serve as CFO at Syndax and partner with Michael and a highly talented and dedicated team,” said Keith A. Goldan, Chief Financial Officer of Syndax. “I am proud of everything we have accomplished together and the positive impact this work continues to have for patients. I am confident Syndax is well positioned for continued success long into the future.”
Mr. Ondrey brings extensive leadership and financial experience across both pre-commercial and commercial-stage biopharmaceutical companies. Most recently, he served as Chief Financial Officer of Beren Therapeutics, where he oversaw finance, investor relations, and manufacturing operations. Prior to joining Beren Therapeutics, Mr. Ondrey served as Chief Financial Officer of Rocket Pharmaceuticals, where he led the company’s financial strategy as it prepared for its transition to a commercial-stage organization. Before Rocket Pharmaceuticals, he was Chief Financial Officer and Senior Vice President at Mirati Therapeutics, where he supported the commercialization of KRAZATI® and played a key role in the company’s acquisition by Bristol Myers Squibb in January 2024. Earlier in his career, Mr. Ondrey held senior leadership positions at Arena Pharmaceuticals, Alexion Pharmaceuticals, and Regeneron Pharmaceuticals, building extensive experience in corporate finance, strategic planning, commercialization, and operational execution.
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company’s pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipate,” “believe,” “could,” “estimate,” “expects,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative or plural of those terms, and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Syndax’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the progress, timing, clinical development and scope of clinical trials, the reporting of clinical data for Syndax’s product candidates, the acceptance of Syndax and its partners’ products in the marketplace, sales, marketing, manufacturing and distribution requirements, and the potential use of its product candidates to treat various cancer indications and fibrotic diseases. Many factors may cause differences between current expectations and actual results, including: unexpected safety or efficacy data observed during preclinical or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; changes to Revuforj’s or Niktimvo’s commercial availability; changes in expected or existing competition; changes in the regulatory environment; failure of Syndax’s collaborators to support or advance collaborations or product candidates; and unexpected litigation or other disputes. Other factors that may cause Syndax’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Syndax’s filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” sections contained therein. Except as required by law, Syndax assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
Syndax Contact
Sharon Klahre Syndax Pharmaceuticals, Inc. sklahre@syndax.com Tel 781.684.9827
All financial figures are in Canadian dollars unless otherwise noted
CALGARY, Alberta, Nov. 02, 2026 (GLOBE NEWSWIRE) — Gibson Energy Inc. (TSX:GEI) (“Gibson” or the “Company”) announced today its financial and operating results for the three and nine months ended September 30, 2026.
Key Highlights:
Delivered record adjusted EBITDA(1) of $193 million and record adjusted EBITDA per share, reflecting strong performance across both Infrastructure and Marketing
Generated record Infrastructure adjusted EBITDA(1) of $177 million and record Infrastructure adjusted EBITDA per share, driven primarily by a full quarter of contributions from the Chauvin Infrastructure Assets
Achieved Marketing adjusted EBITDA(1) of $35 million, supported by continued strength in refined product margins, the benefits of a more diversified product mix, and improved crude marketing opportunities
Sanctioned the Chauvin pipeline expansion, which will increase system capacity by approximately 50%, supported by strong commercial interest and growing production in the Mannville, with an expected in-service date during the first half of 2028
Continued our industry-leading safety performance, surpassing 500 days without a recordable injury while safely bringing the Wink-to-Gateway Integration Project into service and completing the integration of the Chauvin assets into our operations
“Gibson delivered an exceptional third quarter, with record results across the business,” said Curtis Philippon, President & Chief Executive Officer. “Chauvin continues to exceed our expectations, and we are pleased to sanction an expansion that will increase pipeline capacity by approximately 50%. It is a great example of the kind of disciplined infrastructure investment we want to make: supported by our customers, closely connected to our existing assets and capable of delivering attractive returns. In the U.S., we also placed our Wink-to-Gateway Integration Project into service, enhancing connectivity across our network and positioning Gateway to capture additional volumes. With improving Canadian market access and growing producer activity, the opportunity set in front of Gibson is as strong as we have seen in some time. We are well positioned to turn those opportunities into meaningful growth and long-term value for shareholders.”
Financial Highlights:
Infrastructure adjusted EBITDA(1) of $177 million in the third quarter, a $23 million increase from the third quarter of 2025, primarily driven by strong performance from the Chauvin Infrastructure Assets, higher overall throughput, including record volumes moved to TMX through Edmonton, ongoing optimization of our existing assets, and benefits from the Company’s 2026 restructuring initiatives
Marketing adjusted EBITDA(1) of $35 million in the third quarter, a $28 million increase from the third quarter of 2025, primarily driven by strong refining margins resulting from elevated crack spreads, highlighting the benefits of the Company’s product diversification strategy
Adjusted EBITDA(1) on a consolidated basis of $193 million in the third quarter, a $46 million increase from the third quarter of 2025, primarily reflecting stronger Infrastructure and Marketing results and adjustments for unrealized gains and losses on financial instruments in both periods, partially offset by higher General and Administrative costs
Net income of $77 million in the third quarter, a $31 million increase from the third quarter of 2025, primarily due to the factors affecting segment adjusted EBITDA as noted above, partially offset by higher income tax expense and finance costs
Distributable Cash Flow(1) of $120 million in the third quarter, a $34 million increase from the third quarter of 2025, primarily due to the factors contributing to higher adjusted EBITDA as noted above, partially offset by higher finance cost and current income tax expense
Dividend payout ratio(2) of 82% and net debt to adjusted EBITDA(2) ratio of 3.9x on a trailing twelve-month basis, with both metrics expected to improve as a full 12 months of contributions from the Chauvin acquisition are reflected
Strategic Developments and Highlights:
In November, the Board declared a quarterly dividend of $0.45 per common share, payable on January 15, 2027, to shareholders of record at the close of business on December 30, 2026
In October, placed the Wink-to-Gateway Integration Project into service, enhancing connectivity and operational flexibility at Gateway
In September, the Company’s NCIB was renewed for an additional one-year period, enabling the Company to repurchase and cancel up to 7,251,988 common shares, representing 5% of the Company’s public float
In July, the Company closed its offering of $400 million 4.45% senior unsecured medium-term notes due January 9, 2034
(1) Adjusted EBITDA and distributable cash flow are non-GAAP financial measures. See the “Specified Financial Measures” section of this release. (2) Net debt to adjusted EBITDA ratio and dividend payout ratio are non-GAAP financial ratios. See the “Specified Financial Measures” section of this release.
Management’s Discussion and Analysis and Financial Statements The 2026 third quarter Management’s Discussion and Analysis and unaudited Condensed Consolidated Financial Statements provide a detailed explanation of Gibson’s financial and operating results for the three months and nine months ended September 30, 2026, as compared to the three months and nine months ended September 30, 2025. These documents are available at www.gibsonenergy.com and on SEDAR+ at www.sedarplus.ca.
Earnings Conference Call & Webcast Details A conference call and webcast will be held to discuss the 2026 third quarter financial and operating results at 8:00am ABT (9:00am ET) on Tuesday, November 3, 2026.
To register for the call, view dial-in numbers, and obtain a dial-in PIN, please access the following URL:
The webcast will remain accessible for a 12-month period at the above URL.
Supplementary Information Gibson has also made available certain supplementary information regarding the 2026 third quarter financial and operating results, available at www.gibsonenergy.com.
About Gibson Gibson is a leading liquids infrastructure company providing storage, optimization, processing, gathering, and waterborne vessel loading services for liquids and refined products. Headquartered in Calgary, Alberta, the Company’s operations are located across North America, with core terminal assets in Hardisty and Edmonton, Alberta, Ingleside and Wink, Texas, and a facility in Moose Jaw, Saskatchewan.
Gibson shares trade under the symbol GEI and are listed on the Toronto Stock Exchange. For more information, visit www.gibsonenergy.com.
Forward-Looking Statements Certain statements contained in this press release constitute forward-looking information and statements (collectively, “forward-looking statements”). All statements other than statements of historical fact are forward-looking statements. The use of any of the words “expect”, “will” and similar expressions are intended to identify forward-looking statements. Forward-looking statements included or referred to in this press release include, but are not limited to, statements concerning: the development, construction and completion of the Chauvin pipeline expansion project, including its expected increase in system capacity and anticipated in-service date; Gibson’s long-term growth strategy and ability to create long-term shareholder value, including through infrastructure investments capable of delivering attractive returns; Gateway’s positioning to capture additional volumes following the completion of the Wink-to-Gateway Integration Project; improving Canadian market access and growing producer activity, and Gibson’s ability to realize on opportunities relating thereto to produce meaningful growth and create long term value for shareholders; expectations regarding the Company’s dividend payout ratio and net debt to adjusted EBITDA metrics, including their expected improvement and the expected timing and payment of the quarterly dividend. These statements are based on assumptions that the Chauvin pipeline expansion will proceed on the anticipated schedule and within expected costs, with necessary approvals and customer support; that Canadian market access and producer activity will continue to support growth opportunities; that the Chauvin Infrastructure Assets will contribute to Gibson’s financial results as expected; and that customer demand and market conditions will support Gateway’s ability to capture additional volumes as expected. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements. No assurance can be given that these expectations will prove to be correct and such forward-looking statements included in this press release should not be unduly relied upon. These statements speak only as of the date of this press release. The Company does not undertake any obligations to publicly update or revise any forward-looking statements except as required by securities law. Actual results could differ materially from those anticipated in these forward-looking statements as a result of numerous risks and uncertainties including, but not limited to, construction delays or cost overruns on the Chauvin pipeline expansion, changes in producer activity, customer demand or market access, and lower-than-expected contributions from the Chauvin Infrastructure Assets, as well as the risks and uncertainties described in “Forward-Looking Information” and “Risk Factors” included in the Company’s Annual Information Form dated February 17, 2026, and Management’s Discussion and Analysis dated November 2, 2026, as filed on SEDAR+ and available on the Gibson website at www.gibsonenergy.com.
Specified Financial Measures This press release refers to certain financial measures that are not determined in accordance with GAAP, including non-GAAP financial measures and non-GAAP financial ratios. Readers are cautioned that non-GAAP financial measures and non-GAAP financial ratios do not have standardized meanings prescribed by GAAP and, therefore, may not be comparable to similar measures presented by other entities. Management considers these to be important supplemental measures of the Company’s performance and believes these measures are frequently used by securities analysts, investors and other interested parties in the evaluation of companies in industries with similar capital structures.
For further details on these specified financial measures, including relevant reconciliations, see the “Specified Financial Measures” section of the Company’s MD&A for the three and nine months ended September 30, 2026 and 2025, which is incorporated by reference herein and is available on Gibson’s SEDAR+ profile at www.sedarplus.ca and Gibson’s website at www.gibsonenergy.com.
a) Adjusted EBITDA
Noted below is the reconciliation to the most directly comparable GAAP measures of the Company’s segmented and consolidated adjusted EBITDA for the three and nine months ended September 30, 2026, and 2025:
Three months ended September 30,
Infrastructure
Marketing
Corporate and Adjustments
Total
($ thousands)
2026
2025
2026
2025
2026
2025
2026
2025
Segment profit
174,134
149,101
43,589
4,403
—
—
217,723
153,504
Unrealized loss (gain) on derivative financial instruments
1,372
3,503
(9,063
)
2,339
—
—
(7,691
)
5,842
General and administrative
—
—
—
—
(17,997
)
(13,298
)
(17,997
)
(13,298
)
Adjustments to share of profit from equity accounted investee
1,568
1,549
—
—
—
—
1,568
1,549
Renewable virtual power purchase agreement
—
—
—
—
(715
)
(520
)
(715
)
(520
)
Adjusted EBITDA
177,074
154,153
34,526
6,742
(18,712
)
(13,818
)
192,888
147,077
Nine months ended September 30,
Infrastructure
Marketing
Corporate and Adjustments
Total
($ thousands)
2026
2025
2026
2025
2026
2025
2026
2025
Segment profit
491,016
459,820
60,235
27,331
—
—
551,251
487,151
Unrealized loss (gain) on derivative financial instruments
6,751
(2,177
)
(7,825
)
(12,816
)
—
—
(1,074
)
(14,993
)
General and administrative
—
—
—
—
(52,668
)
(40,638
)
(52,668
)
(40,638
)
Adjustments to share of profit from equity accounted investee
4,690
3,896
—
—
—
—
4,690
3,896
Executive transition costs
—
—
—
—
—
2,405
—
2,405
Renewable virtual power purchase agreement
—
—
—
—
(1,732
)
(2,142
)
(1,732
)
(2,142
)
Adjusted EBITDA
502,457
461,539
52,410
14,515
(54,400
)
(40,375
)
500,467
435,679
Three months ended September 30,
($ thousands)
2026
2025
Net Income
77,026
45,694
Income tax expense
27,302
12,439
Depreciation, amortization, and impairment charges
48,905
43,398
Finance costs, net
39,621
35,094
Unrealized (gain) loss on derivative financial instruments
(8,190
)
5,842
Unrealized loss (gain) on renewable virtual power purchase agreement
73
(1,436
)
Share-based compensation
5,210
4,104
Acquisition and integration costs
970
—
Adjustments to share of profit from equity accounted investee
1,568
1,549
Corporate foreign exchange loss and other
403
393
Adjusted EBITDA
192,888
147,077
Nine months ended September 30,
($ thousands)
2026
2025
Net Income
158,558
156,346
Income tax expense
52,245
46,580
Depreciation, amortization, and impairment charges
145,860
128,923
Finance costs, net
113,567
103,329
Unrealized gain on derivative financial instruments
(1,573
)
(14,993
)
Unrealized gain on renewable virtual power purchase agreement
(22
)
(9,180
)
Share-based compensation
14,306
11,826
Restructuring costs
8,125
—
Acquisition and integration costs
6,162
—
Adjustments to share of profit from equity accounted investee
4,690
3,896
Corporate foreign exchange (gain) loss and other
(1,451
)
6,547
Executive transition costs
—
2,405
Adjusted EBITDA
500,467
435,679
b) Distributable Cash Flow
The following is a reconciliation of distributable cash flow from operations to its most directly comparable GAAP measure, cash flow from operating activities:
Three months ended September 30,
Nine months ended September 30,
($ thousands)
2026
2025
2026
2025
Cash flow from operating activities
212,583
195,572
429,766
416,804
Adjustments:
Changes in non-cash working capital and taxes paid
(24,418
)
(50,826
)
42,825
7,526
Replacement capital
(14,629
)
(12,863
)
(37,448
)
(33,326
)
Cash interest expense, including capitalized interest
(37,486
)
(33,413
)
(107,074
)
(97,341
)
Acquisition and integration costs
970
—
6,162
—
Restructuring costs (1)
—
—
6,125
—
Executive transition costs (1)
—
—
—
2,405
Lease payments
(6,780
)
(5,353
)
(19,889
)
(18,448
)
Current income tax
(10,579
)
(7,567
)
(30,821
)
(20,016
)
Distributable cash flow
119,661
85,550
289,646
257,604
Twelve months ended September 30,
($ thousands)
2026
2025
Cash flow from operating activities
523,121
484,080
Adjustments:
Changes in non-cash working capital and taxes paid
88,231
61,504
Replacement capital
(51,962
)
(45,053
)
Cash interest expense, including capitalized interest
WATERTOWN, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) — C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the directors serving on the Organization, Leadership and Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase 85,480 shares of the Company’s common stock to one new employee (the “Inducement Grant”), with the grant made on November 2, 2026 (the “Grant Date”). The Inducement Grant was granted as a material inducement to this individual entering employment with C4T in accordance with Nasdaq Listing Rule 5635(c)(4).
The Inducement Grant has an exercise price per share that is equal to the closing price of C4T’s common stock on the Grant Date. The Inducement Grant will vest over a four-year period, with 25% of the shares vesting on the first-year anniversary of the employee’s start date, with the remainder of the shares vesting in thirty-six equal monthly installments thereafter, subject to the employee’s continued employment with C4T through each vesting date.
About C4 Therapeutics C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com.
– Total revenue of $83.3 million in 3Q26, an 82% year-over-year increase –
– Revuforj® (revumenib) net revenue of $60.7 million in 3Q26, a 90% y/y increase, underscores leadership in R/R NPM1m and KMT2Ar acute leukemia; 20% q/q growth in new patients –
– Niktimvo™ (axatilimab-csfr) net revenue of $67.4 million in 3Q26, a 47% y/y increase, resulting in Syndax collaboration revenue of $22.6 million –
– New revumenib data expected in 4Q26 from clinical trials and real-world studies spanning the acute leukemia treatment continuum and multiple genetic subtypes –
– Company to host a conference call today at 4:30 p.m. ET –
NEW YORK, Nov. 02, 2026 (GLOBE NEWSWIRE) — Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today reported its financial results for the third quarter ended September 30, 2026, and provided a business update.
“We delivered another quarter of strong commercial results, generating $83 million in total revenue to Syndax. Revuforj net revenue grew to $61 million, driven by a 20% increase in new patients and an increasing number of patients on therapy in the post-transplant setting. We continue to have the dominant share of new patients across all age groups starting a menin inhibitor and the vast majority of revenue for the class, underscoring our position as the market leader. Importantly, a growing number of both R/R KMT2Ar and NPM1m patients are proceeding to a stem cell transplant after receiving Revuforj and then resuming therapy afterward, a dynamic that positions the business for long-term growth as the average duration of therapy extends,” said Michael A. Metzger, Chief Executive Officer.
Mr. Metzger continued, “We look forward to sharing new Revuforj combination data in the fourth quarter that reinforce our confidence that our ongoing pivotal frontline trials could transform the treatment paradigm for newly diagnosed AML. We remain well positioned to be the first to deliver a menin inhibitor in the frontline, unlocking a multi-billion-dollar opportunity. With growing revenue from two medicines, a robust pipeline generating multiple blockbuster opportunities, world-class R&D capabilities, and a strong balance sheet, Syndax is poised to deliver long-term value.”
Recent Business Highlights and Anticipated Milestones
Revuforj® (revumenib)
Achieved $60.7 million in Revuforj net revenue in the third quarter of 2026, a 90% increase over the third quarter of 2025 and an 11% increase over the second quarter of 2026. New patients and total prescriptions increased by approximately 20% and 13%, respectively, in the third quarter of 2026 compared to the second quarter of 2026. The double-digit growth in net revenue, new patients, and total prescriptions reflects robust uptake in both Revuforj indications and a growing number of relapsed or refractory (R/R) KMT2A-rearranged (KMT2Ar) and NPM1-mutated (NPM1m) patients proceeding to hematopoietic stem cell transplant (HSCT) and then resuming therapy in the post-transplant setting.
Claims data indicate that approximately 50% of R/R KMT2Ar patients proceed to HSCT after receiving Revuforj, of which about 60% have resumed therapy post-transplant. Notably, the data also indicate that approximately 40% of R/R NPM1m patients proceed to HSCT after receiving Revuforj, of which about 50% have resumed therapy post-transplant.
In October 2026, Revuforj received the Best Product for Rare/Orphan Diseases award from The Galien Foundation, one of the world’s most prestigious awards for biomedical research and innovation. Additionally, Revuforj was named as one of TIME’s Best Inventions of 2026 in the Medical and Healthcare category.
The Company expects to have a major presence at upcoming medical meetings, with the presentation in the fourth quarter of 2026 of new/updated revumenib data including:
Frontline data from the BEAT AML trial of revumenib in combination with venetoclax/azacitidine in NPM1m and KMT2Ar acute myeloid leukemia (AML)
Frontline data from the SAVE trial of the all-oral combination of revumenib, decitabine/cedazuridine, and venetoclax in NPM1m, KMT2Ar, or NUP98-rearranged (NUP98r) AML
Frontline data from a Phase 1 trial of revumenib in combination with intensive chemotherapy in NPM1m, KMT2Ar, or NUP98r AML
Post-transplant maintenance data
Real-world evidence from multiple centers
Data from INTERCEPT, a Phase 1 trial evaluating revumenib as pre-emptive therapy for measurable residual disease (MRD) or early relapse among patients with NPM1m or KMT2Ar AML
The Company expects to publish safety and efficacy data from R/R NUP98r acute leukemia patients treated with revumenib in the fourth quarter of 2026.
Published preclinical revumenib data showing that menin is a novel dependency in proliferative megakaryocytes, major drivers of myelofibrosis (MF), in Cancer Cell in July 2026. These data provide the basis for the Company’s plans to develop SNDX-62122, an internally developed, next-generation menin inhibitor, for MF.
Multiple clinical trials evaluating revumenib across the acute leukemia treatment continuum are ongoing, such as:
EVOLVE-2: A pivotal, Phase 3, randomized, double-blind, placebo-controlled trial of revumenib in combination with venetoclax and azacitidine in newly diagnosed NPM1m (primary efficacy analysis population) and KMT2Ar AML patients who are unfit for intensive chemotherapy. The trial is being conducted in collaboration with the HOVON network, a leading cooperative clinical trial group with extensive experience studying novel therapies for hematologic malignancies.
REVEAL-ND: A pivotal, Phase 3, randomized, double-blind, placebo-controlled trial of revumenib in combination with intensive chemotherapy in newly diagnosed NPM1m AML patients.
SAVE: A Phase 1/2 trial evaluating an all-oral combination of revumenib with venetoclax and decitabine/cedazuridine in pediatric and adult patients with newly diagnosed and R/R AML or mixed-lineage acute leukemia harboring either NPM1m, KMT2Ar, or NUP98r alterations. The trial is being conducted by investigators from MD Anderson Cancer Center.
Intensive chemotherapy: Two ongoing Phase 1 trials evaluating the combination of revumenib with intensive chemotherapy (7+3) in newly diagnosed NPM1m or KMT2Ar acute leukemia patients.
BEAT AML: A Phase 1b trial evaluating the combination of revumenib with venetoclax and azacitidine in newly diagnosed older adults (≥60 years) with NPM1m or KMT2Ar AML. The trial is being conducted as part of the Leukemia & Lymphoma Society’s Beat AML® Master Clinical Trial.
Post-transplant maintenance: A Phase 1 trial evaluating the safety and preliminary efficacy of revumenib as post-transplant maintenance in patients with KMT2Ar or NPM1m acute leukemia. The trial is being conducted by investigators from the City of Hope Medical Center.
Break Through Cancer: A Phase 2 trial studying whether the combination of revumenib and venetoclax can eliminate MRD in patients with AML and extend progression-free survival. The trial is being conducted by Break Through Cancer, a collaboration between leading U.S. cancer research centers.
INTERCEPT: A Phase 1 trial evaluating the use of novel therapies, including revumenib, to target MRD and early relapse in AML. The trial is being conducted by the Australasian Leukaemia and Lymphoma Group as part of the INTERCEPT AML master clinical trial.
The Company expects the RAVEN trial to initiate in the fourth quarter of 2026. RAVEN is a Phase 2 collaborative trial of revumenib in combination with venetoclax and azacitidine in newly diagnosed KMT2Ar patients who would be considered eligible, or fit, for intensive chemotherapy.
The Company expects the MenTain Phase 2 trial to initiate in the first quarter of 2027. MenTain will be the first randomized, placebo-controlled trial specifically focused on evaluating revumenib as post-transplant maintenance.
Niktimvo™ (axatilimab-csfr)
Achieved $67.4 million in Niktimvo net revenue in the third quarter of 2026, a 47% increase over the third quarter of 2025 and a 12% increase over the second quarter of 2026. Syndax and Incyte are co-commercializing Niktimvo. Syndax records 50% of the Niktimvo net commercial profit, defined as net product revenue minus the cost of sales and commercial expenses. Syndax’s share of the Niktimvo product contribution, reported as collaboration revenue, was $22.6 million in the third quarter of 2026.
In October 2026, data supporting the safety and feasibility of reduced-frequency dosing of axatilimab in patients with recurrent or refractory chronic graft-versus-host disease (GVHD) were published in Blood Advances. Data from the pivotal AGAVE-201 trial show that transition from axatilimab 0.3 mg/kg every two weeks to 0.6 mg/kg every four weeks was feasible and well tolerated. Patients had a prolonged duration of therapy after the switch (median of 21 months), and 84% remained on treatment as of the data cutoff, suggesting ongoing clinical benefit.
Two trials evaluating axatilimab in patients with newly diagnosed chronic GVHD are ongoing, including a Phase 2 trial in combination with ruxolitinib and a Phase 3 trial in combination with corticosteroids.
The Company expects topline data from the Phase 2 trial of axatilimab in combination with ruxolitinib to be presented at a medical meeting in the first quarter of 2027.
The Company expects topline data from the Phase 3 trial of axatilimab in combination with corticosteroids in early 2028.
In October 2026, the Company announced that the MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis (IPF) did not meet its primary endpoint. The safety and tolerability profile observed in MAXPIRe was consistent with previous clinical studies of axatilimab, with no new safety signals identified. Based on the results observed, Syndax does not plan to move forward with further development of axatilimab in IPF. The results from the MAXPIRe trial do not affect ongoing trials of axatilimab in other potential indications.
Pipeline Assets
SNDX-4321
In July 2026, the Company announced the expansion of its pipeline with SNDX-4321, a mutant-selective, CNS-penetrant, allosteric EGFR inhibitor. SNDX-4321 is in development for non-small cell lung cancer (NSCLC) patient populations with significant unmet needs, such as those with L858R mutations, CNS metastases, atypical activating mutations, or acquired resistance to current therapies. In contrast to ATP-site directed third- and fourth-generation EGFR inhibitors, SNDX-4321 is a novel allosteric inhibitor which binds at a pocket adjacent to the ATP site that is only accessible in the presence of L858R and certain other EGFR mutations.
The Company expects to submit an investigational new drug (IND) application for SNDX-4321 by the end of 2026 and to initiate a Phase 1 trial in EGFRm NSCLC in 2027.
SNDX-62122
In July 2026, the Company announced the selection of SNDX-62122, a next-generation menin inhibitor, for development in MF. SNDX-62122 is the first candidate from a library of internally developed, wholly owned next-generation menin inhibitors that the Company intends to advance into new areas.
The Company expects to submit an IND and initiate a Phase 1 trial of SNDX-62122 in MF in the fourth quarter of 2027. The development of SNDX-62122 will be informed by a Phase 1/2 proof-of-principle trial of revumenib in MF that is expected to initiate in the fourth quarter of 2026 with initial clinical data expected in the second half of 2027.
Corporate Updates
On November 2, 2026, the Company announced Keith Goldan’s decision to retire from his role as Chief Financial Officer and the appointment of Aaron A. Ondrey as Chief Financial Officer, effective November 9, 2026. Mr. Ondrey brings to Syndax more than 25 years of financial and operational leadership experience across the biotechnology industry, with deep expertise in financial management, corporate strategy, commercialization, and mergers and acquisitions.
Third Quarter 2026 Financial Results
As of September 30, 2026, Syndax had cash, cash equivalents, and short- and long-term investments of $551.1 million and 90.0 million common shares outstanding.
Total revenue for the third quarter of 2026 was $83.3 million, which consisted of $60.7 million in Revuforj net revenue and $22.6 million in Niktimvo collaboration revenue. The Niktimvo collaboration revenue is derived from the $67.4 million in Niktimvo net revenue that was previously reported by the Company’s partner Incyte for the third quarter 2026. Syndax records 50% of the Niktimvo net commercial profit, defined as net revenue (recorded by Incyte) minus the cost of sales and commercial expenses.
Third quarter 2026 research and development expenses increased to $67.5 million from $56.3 million for the comparable prior year period. The year-over-year change was primarily the result of increased expenses associated with frontline trials evaluating revumenib in combination with standard-of-care agents in the treatment of AML.
Third quarter 2026 selling, general and administrative expenses decreased to $43.7 million from $44.9 million for the comparable prior year period. The year-over-year change was primarily the result of lower commercial expenses due to launch costs incurred in 2025 for Revuforj and Niktimvo that were not incurred in the same period in 2026.
For the three months ended September 30, 2026, Syndax reported a net loss attributable to common stockholders of $49.4 million, or $0.55 per share, compared to a net loss attributable to common stockholders of $60.7 million, or $0.70 per share, for the comparable prior year period.
Financial Guidance
For the full year of 2026, the Company continues to expect total research and development plus selling, general and administrative expenses to be approximately $400 million, excluding the impact of $50 million in estimated non-cash stock compensation expense.
Syndax expects that its cash, cash equivalents and short- and long-term investments, combined with its anticipated product revenue, collaboration revenue and interest income, will enable the Company to reach profitability.
Conference Call and Webcast
In connection with the earnings release, Syndax’s management team will host a conference call and live audio webcast at 4:30 p.m. ET today, November 2, 2026.
The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company’s website. Alternatively, the conference call may be accessed through the following:
Conference ID: Syndax3Q26 Domestic Dial-in Number: 800-590-8290 International Dial-in Number: 240-690-8800 Live webcast: https://sndx-3q26.open-exchange.net/
For those unable to participate in the conference call or webcast, a replay will be available on the Investors section of the Company’s website at www.syndax.com approximately 24 hours after the conference call and will be available for 90 days following the call.
AboutRevuforj® (revumenib)
Revuforj (revumenib) is the first and only menin inhibitor that is FDA approved for the treatment of adult and pediatric patients one year and older with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible NPM1 mutation who have no satisfactory alternative treatment options or R/R acute leukemia with a KMT2A translocation as determined by an FDA-authorized test.
Multiple trials of revumenib are ongoing or planned across the treatment landscape, including in combination with standard of care therapies in newly diagnosed patients with NPM1m or KMT2Ar AML.
About Niktimvo™ (axatilimab-csfr)
Niktimvo (axatilimab-csfr) is a first-in-class colony stimulating factor-1 receptor (CSF-1R)-blocking antibody approved for use in the U.S. for the treatment of chronic graft-versus-host disease (GVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg (88.2 lbs).
In 2016, Syndax licensed exclusive worldwide rights to develop and commercialize axatilimab from UCB. In September 2021, Syndax and Incyte entered into an exclusive worldwide co-development and co-commercialization license agreement for axatilimab in chronic GVHD and any future indications.
Axatilimab is being studied in frontline combination trials in chronic GVHD, including a Phase 2 combination trial with ruxolitinib (NCT06388564) and a Phase 3 combination trial with steroids (NCT06585774).
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company’s pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com/ or follow the Company on X and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipate,” “believe,” “could,” “estimate,” “expects,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative or plural of those terms, and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Syndax’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the progress, timing, clinical development and scope of clinical trials, the reporting of clinical data for Syndax’s product candidates, the acceptance of Syndax and its partners’ products in the marketplace, sales, marketing, manufacturing and distribution requirements, the potential use of its product candidates to treat various cancer indications and fibrotic diseases, Syndax’s expected full year total operating expenses, including its estimated non-cash stock compensation expense, and Syndax’s expectation that its cash, cash equivalents and short-term investments, combined with its anticipated product revenue, collaboration revenue and interest income, will enable the Company to reach profitability. Many factors may cause differences between current expectations and actual results, including: unexpected safety or efficacy data observed during preclinical or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; changes to Revuforj’s or Niktimvo’s commercial availability; changes in expected or existing competition; changes in the regulatory environment; failure of Syndax’s collaborators to support or advance collaborations or product candidates; and unexpected litigation or other disputes. Other factors that may cause Syndax’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Syndax’s filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” sections contained therein. Except as required by law, Syndax assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
Niktimvo is a trademark of Incyte. All other trademarks are the property of their respective owners.
Syndax Contact Sharon Klahre Syndax Pharmaceuticals, Inc. sklahre@syndax.com Tel 781.684.9827
SNDX-G
SYNDAX PHARMACEUTICALS, INC.
(unaudited)
CONDENSED CONSOLIDATED BALANCE SHEETS
September 30,
December 31,
(In thousands)
2026
2025
Cash, cash equivalents, short and long-term investments
$
551,079
$
394,070
Total assets
$
692,671
$
529,706
Total liabilities
$
709,851
$
465,076
Total stockholders’ (deficit) equity
$
(17,180
)
$
64,630
Common stock outstanding
89,989,347
87,405,979
Common stock and common stock equivalents*
116,512,240
103,437,561
*Common stock and common stock equivalents:
Common stock
89,989,347
87,405,979
Common stock warrants (pre-funded)
–
285,714
Common stock and pre-funded stock warrants
89,989,347
87,691,693
Options to purchase common stock
13,302,121
13,128,306
Restricted Stock Units
3,123,422
2,617,562
Conversion of convertible notes
10,097,350
–
Total common stock and common stock equivalents
116,512,240
103,437,561
SYNDAX PHARMACEUTICALS, INC.
(unaudited)
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
Three Months Ended September 30,
Nine Months Ended September 30,
(In thousands, except share and per share data)
2026
2025
2026
2025
Revenue
Product revenue, net
$
60,743
32,007
$
164,366
80,649
Collaboration revenue, net
22,555
13,864
56,584
22,975
Total revenues
83,298
45,871
220,950
103,624
Operating expenses:
Cost of product sales
$
13,996
2,100
$
19,837
4,264
Research and development
67,481
56,280
194,362
180,143
Selling, general and administrative
43,716
44,917
122,843
129,753
Total operating expenses
125,193
103,297
337,042
314,160
Loss from operations
(41,895
)
(57,426
)
(116,092
)
(210,536
)
Other (expense) income, net:
Royalty interest expense
(11,812
)
(8,283
)
(35,777
)
(24,186
)
Convertible note interest expense
(1,164
)
–
(1,719
)
–
Other interest expense
(2
)
–
(4
)
(6
)
Interest income
5,593
5,269
12,900
18,402
Other expense
(153
)
(275
)
(777
)
(1,082
)
Total other (expense) income, net
(7,538
)
(3,289
)
(25,377
)
(6,872
)
Net loss
$
(49,433
)
$
(60,715
)
$
(141,469
)
$
(217,408
)
Other comprehensive loss:
Unrealized (loss) gain on marketable securities
(1,528
)
240
(2,120
)
362
Other comprehensive loss
(50,961
)
(60,475
)
(143,589
)
(217,046
)
Net loss per share:
Basic and diluted loss per share attributable to common stockholders
$
(0.55
)
$
(0.70
)
$
(1.59
)
$
(2.51
)
Weighted-average common shares used in calculating:
Basic and diluted loss per share attributable to common stockholders
